Pneumococcal vaccine
Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$39–145
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
2
Tier A · 77 studies
Source agreement
material
sources differ
Scope to country:All countries
Cost-effectiveness
Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.
Modeled benchmarks ($/DALY)Tier A · standardized benchmark
WHO-CHOICE estimates are modeled at 50% population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →
$/DALY sources differ by 3.7x - a material difference.
Modeled regional estimates — not realized delivery costs.
Published study estimates ($/DALY)Tier B · context only
Tufts GHCEA · 77 studies, varied methods — explore the spread, not a single number.
Health-system
$1,304
median · n=33
Mixed
$500
median · n=25
Societal
$342
median · n=19
Filter the cohort
$664median of 77 studies · IQR $148–$1,588 · 4 cost-saving
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Looking for supply/market data for Pneumococcal vaccine? Select a country above, then open its intelligence page.